These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease]. Kulisevsky J Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622 [TBL] [Abstract][Full Text] [Related]
18. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081 [TBL] [Abstract][Full Text] [Related]
19. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229 [TBL] [Abstract][Full Text] [Related]
20. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]